A practical reference on GHRH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-22 and is reviewed periodically as new material appears.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
== Career == Ruoslahti held various academic appointments with the University of Helsinki and the University of Turku in Finland and City of Hope National Medical Center in Duarte, California until joining the La Jolla Cancer Research Foundation (now Sanford Burnham Prebys Medical Discovery Institute, or SBP) in 1979. He had moved from Finland to the United States in 1976. He served as SBP's president from 1989 to 2002, and was a distinguished professor at the University of California, Santa Barbara from 2005 to 2015. He has received U.S. citizenship.
From the 1830s Haüy's molecular crystal structure theory started to be combined with the atomic theory of the chemists to produce a view of a crystal as the regular arrangement of atoms or molecules in space. In 1849 Auguste Bravais related the symmetry of the crystal, considered as one of 14 space lattices, to that of its constituting molecules and formalized the reticular interpretation of hemihedry given by Gabriel Delafosse. In 1852 Delafosse attempted to relate the structure of the molecule to the external shape of the crystal. During the 1850s and 1860s a "quiet revolution" took place in structural chemistry according to Alan J. Rocke, a historian of chemistry. The main features of the revolution were the clarification of the concept of atomic weight (Stanislao Cannizzaro), the definition of the idea of valence (then known as atomicity), and new chemical structural ideas, such as the benzene structure of a ring of alternating double and single carbon bonds (August Kekulé). These developments in chemistry were largely independent of the mathematical and geometrical direction of crystallography in the period 1850–1895 which had little concern with the practicalities of atomic and molecular arrangement. In 1869 Emanuele Paternò predicted that the four valences of carbon have identical chemical properties and illustrated three predicted isomers of dibromethane showing the tetrahedral carbon atom for the first time. While Paternò's work was the first publication of tetrahedral-valent carbon it is not clear that he recognized the full consequences of the hypothesis.
=== Metal cation binding === Polyanionic and featuring a potentially chelating polyphosphate group, ATP binds metal cations with high affinity. The binding constant for Mg2+ is (9554). The binding of a divalent cation, almost always magnesium, strongly affects the interaction of ATP with various proteins. Due to the strength of the ATP-Mg2+ interaction, ATP exists in the cell mostly as a complex with Mg2+ bonded to the phosphate oxygen centers. A second magnesium ion is critical for ATP binding in the kinase domain. The presence of Mg2+ regulates kinase activity. It is interesting from an RNA world perspective that ATP can carry a Mg2+ ion which catalyzes RNA polymerization.
Sources: en.wikipedia.org
=== Foe === A foe is a unit of energy equal to 1044 joules (≈9.478×1040 BTU) that was invented by physicist Gerry Brown of Stony Brook University. To measure the staggeringly immense amount of energy produced by a supernova, specialists occasionally use the "foe", an acronym derived from the phrase [ten to the power of] fifty-one ergs, or 1051 ergs. This unit of measure is convenient because a supernova typically releases about one foe of observable energy in a very short period of time (which can be measured in seconds).
=== Very long-chain acyl-Coenzyme A dehydrogenase (VLCAD) deficiency === Very long-chain acyl-coenzyme A dehydrogenase deficiency (VLCAD deficiency) is a genetic disorder that affects the body's ability to break down certain fats. In the β-oxidation cycle, VLCAD's role involves the removal of two hydrogen atoms from the acyl-CoA molecule, forming a double bond and converting it into trans-2-enoyl-CoA. This crucial first step in the cycle is essential for the fatty acid to undergo further processing and energy production. When there is a deficiency in VLCAD, the body struggles to effectively break down long-chain fatty acids. This can lead to a buildup of these fats and a shortage of energy, particularly during periods of fasting or increased physical activity. Symptoms
Warren and Senator Richard Blumenthal of Connecticut asked the Department of Justice and Securities and Exchange Commission to investigate whether senior bank executives had violated any laws. Senator John Kennedy of Louisiana criticized regulators for lax oversight of the bank. The Bank Policy Institute, which represents large banks, contended that the failures of SVB and Signature Bank were primarily caused by failures of management and supervision, rather than regulation, and stressed its members' resiliency. Several Republicans and conservative commentators argued that the bank failed because it was "woke" and distracted by its workforce diversity efforts, which are typical of mid-sized and large banks in the U.S. Florida Governor Ron DeSantis, Representative Marjorie Taylor Greene of Georgia, and Tucker Carlson tied the bank's failure to its diversity, equity, and inclusion (DEI) program. Greene and Representative James Comer of Kentucky cited the bank's environmental, social, and corporate governance investment program. Senator Tim Scott of South Carolina implied that the San Francisco Fed overlooked risks at the bank due to a shared focus on climate change. Andy Kessler suggested that the presence of minorities and military veterans on the bank's board of directors served as a distraction. The New York Post blamed the DEI efforts of a manager at the UK subsidiary for the risks that arose in the U.S.
Sources: en.wikipedia.org
This money was used for improvements and security enhancements at research and storage facilities. Safety of nuclear facilities in Russia has been significantly improved since the stabilization of political and economical turmoil of the early 1990s. For example, in 1993 there were 29 incidents ranking above level 1 on the International Nuclear Event Scale, and this number dropped under four per year in 1995–2003. The number of employees receiving annual radiation doses above 20 mSv, which is equivalent to a single full-body CT scan, saw a strong decline around 2000. In November 2015, the Russian government approved a federal program for nuclear and radiation safety for 2016 to 2030 with a budget of 562 billion rubles (ca. 8 billion USD). Its key issue is "the deferred liabilities accumulated during the 70 years of the nuclear industry, particularly during the time of the Soviet Union". About 73% of the budget will be spent on decommissioning aged and obsolete nuclear reactors and nuclear facilities, especially those involved in state defense programs; 20% will go in processing and disposal of nuclear fuel and radioactive waste, and 5% into monitoring and ensuring of nuclear and radiation safety.
Engineered yeast-based platform Synthetic biologists are developing genetically modified live yeast that can deliver therapeutic biologic medicines. When orally delivered, these live yeast act like micro-factories and will make therapeutic molecules directly in the gastrointestinal tract. Because yeast are eukaryotic, a key benefit is that they can be administered together with antibiotics. Probiotic yeast expressing human P2Y2 purinergic receptor suppressed intestinal inflammation in mouse models of inflammatory bowel disease. A live S. boulardii yeast delivering a tetra-specific anti-toxin that potently neutralizes Toxin A and Toxin B of Clostridioides difficile has been developed. This therapeutic anti-toxin is a fusion of four single-domain antibodies (nanobodies) that potently and broadly neutralize the two major virulence factors of C. difficile at the site of infection in preclinical models. The first in human clinical trial of engineered live yeast for the treatment of Clostridioides difficile infection is anticipated in 2024 and will be sponsored by the developer Fzata, Inc.
Soybeans have the smallest sample food that provide complete protein, smaller than for several animal foods. Food samples for nuts, seeds, beans, and peas are bigger than one of chicken, and in case of rice, the sample is simply unpractical - the known fact is that cereals are not the main source of proteins.
=== Non-tuberculous mycobacteria === Isoniazid may also be used off-label to treat nontuberculous mycobacterial pulmonary disease. Isoniazid was widely used in the treatment of Mycobacterium avium complex as part of a regimen including rifampicin and ethambutol. Evidence suggests that isoniazid prevents mycolic acid synthesis in M. avium complex as in M. tuberculosis and although this is not bactericidal to M. avium complex, it greatly potentiates the effect of rifampicin.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.